Stockholders' Equity (Details Narrative) - USD ($)						1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	May 22, 2020	May 21, 2020	Apr. 10, 2020	Apr. 04, 2013	Apr. 30, 2018	Nov. 30, 2017	Oct. 31, 2017	Apr. 30, 2015	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jan. 31, 2020	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2005
Proceeds from issuance of preferred stock												$ 1,700,000
Number of options and warrants, outstanding											12,111,333			12,111,333		12,111,333	12,116,334
Number of options and warrants, exercisable	12,111,333											12,111,333		12,111,333
Weighted average exercise price, outstanding											$ 0.62			$ 0.62		$ 0.62	$ 0.62
Weighted average exercise price, exercisable	$ 0.62											$ 0.62		$ 0.62
Weighted average remaining life, exercisable												3 years 9 months 25 days		4 years 8 months 2 days
Shares issued value												$ 1,531,446
Proceeds from debt												$ 181,156	$ 145,076
Equity Incentive Plan [Member]
Number of options and warrants, outstanding	14,811,333											14,811,333
Number of options and warrants, exercisable	14,811,333											14,811,333
Weighted average exercise price, outstanding	$ 0.62											$ 0.62
Weighted average exercise price, exercisable	$ 0.62											$ 0.62
Weighted average remaining life, outstanding												3 years 9 months 25 days
Weighted average remaining life, exercisable												3 years 9 months 25 days
Common Stock [Member]
Number of shares issued during period
Shares issued value
Common Stock [Member] | Equity Incentive Plan [Member]
Number of common shares reserved for issuance																		283,058
Series B Convertible Preferred Stock [Member]
Shares conversion price, per share			$ 0.0113
Debt conversion of convertible shares			88.5
Conversion description			If the Company sells shares of Common Stock or Common Stock equivalents at a price less than the current conversion price, the conversion price of the Series B Convertible Preferred Stock will be reduced to equal eighty percent (80%) of the price at which such Common Stock or Common Stock equivalents are sold.
Discription liquidation			Upon any liquidation, dissolution or winding up of our company, after payment or provision for payment of our debts and other liabilities and before any distribution or payment is made to the holders of our common stock or any junior securities, the holders of our Series B Convertible Preferred Stock will first be entitled to be paid an amount equal to $1.00 per share plus any other fees, liquidated damages or dividends then owing, before our remaining assets will be distributed among the holders of the other classes or series of shares of our capital stock in accordance with our Certificate of Incorporation.
Series B Preferred Stock [Member]
Preferred stock, outstanding	1,700,000											1,700,000
Series A Convertible Preferred Stock [Member]
Preferred stock, outstanding	602											602		790
Shanxi Taxus Pharmaceuticals Co. Ltd. [Member] | Excellagen [Member]
Distribution and license rights description				A Distribution and License Agreement with Shanxi (as amended, the "Shanxi License Agreement"), granting Shanxi certain license rights with respect to our Generx product candidate. The distribution and license rights commence only after we obtain U.S. FDA approval for marketing and sale of Generx in the United States. The license rights include (a) a non-exclusive right to manufacture Generx products in China, and (b) an exclusive right to market and sell Generx products in Singapore, Macau, Hong Kong, Taiwan, any other municipality other than mainland China where Chinese (Mandarin or Cantonese) is the common language, the Russian Federation, and the Commonwealth of Independent States (i.e., Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan).
Shanxi Taxus Pharmaceuticals Co. Ltd. [Member] | Excellagen [Member] | Maximum [Member]
Royalty income				$ 3,350,000
Subscription payment				$ 600,000
Royalty range				10.00%
Shanxi Taxus Pharmaceuticals Co. Ltd. [Member] | Excellagen [Member] | Minimum [Member]
Royalty range				5.00%
Director [Member]
Serving term		1 year
Nostrum Pharmaceuticals, LLC [Member]
Equity, shares ownership percentage		91.20%
Debt instrument issued in exchange of cash															$ 25,000
Debt interest rate															6.00%
Proceeds from debt	$ 265,000
Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | Common Stock [Member]
Debt conversion of convertible shares		88,496
Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Preferred Stock [Member]
Number of shares issued during period		1,700,000
Shares conversion price, per share		$ 0.0113
Debt conversion of convertible shares		150,442,478
Shares issued value		$ 1,700,000
Legal costs		$ 166,891
Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member]
Number of common shares sold during period									600,000
Proceeds from common stock issued									$ 600,000
Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member] | Angionetics, Inc [Member]
Proceeds from common stock issued									3,000,000
Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member] | Angionetics, Inc [Member] | Tranches [Member]
Proceeds from common stock issued									$ 3,000,000
Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member]
Equity, shares ownership percentage, description					Sabby is limited to hold no more than 10% of Gene Biotherapeutics' issued and outstanding common stock at any time.
Preferred stock, outstanding	602											602		790
Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member] | Convertible Series A Preferred Stock [Member]
Number of shares issued during period					4,012
Proceeds from issuance of preferred stock					$ 4,000,000
Shares conversion price, per share					$ 0.6437
Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member] | Convertible Series B Preferred Stock [Member]
Shares conversion price, per share					$ 0.0113
Landmark Pegasus, Inc. [Member] | Warrant [Member]
Warrants issued during period						1,000,000		1,000,000
Warrants exercisable, description						The Common Stock warrants are exercisable at any time from April 23, 2018 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, April 22, 2028, at an exercise price of $0.25 per share.		The warrants are exercisable at any time from October 9, 2017 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, October 8, 2027, at an exercise price of $0.25 per share.
Warrants exercise price, per share						$ 0.25		$ 0.25
Warrants fair value, per share						$ 0.08		$ 0.15
Consulting costs										$ 80,000	$ 150,000
Consultant [Member] | Warrant [Member]
Warrants issued during period							700,000
Warrants exercisable, description							The warrants are exercisable at any time from November 14, 2017 (the grant date) for a period up to 10 years at an exercise price of $0.25 per share.
Warrants exercise price, per share							$ 0.25
Warrants fair value, per share							$ 0.11
Consulting costs											$ 79,222
Sabby Master Healthcare Ltd [Member] | Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series A Preferred Stock [Member]
Number of shares issued during period		220
Common stock issued and outstanding percentage		9.99%
Sabby Master Healthcare Ltd [Member] | Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]
Number of shares issued during period		570